Key highlights:

  • 1-for-10 Reverse Stock Split effective May 21, 2026, reducing shares from 11.4 million to 1.14 million
  • Reverse split designed to regain compliance with Nasdaq's $1.00 minimum bid price rule
  • Pending reverse Takeover to acquire Realbotix LLC, an AI-powered humanoid robotics company
  • Authorised Capital/">Share Capital unchanged, preserving flexibility for future issuance
  • Represents a full strategic pivot away from oncology into the AI robotics sector

Onconetix, Inc. (NASDAQ: ONCO) has announced a significant corporate restructuring move that signals a dramatic strategic shift for the company. The Board of Directors has approved a 1-for-10 reverse stock split of its common stock, set to take effect at market open on May 21, 2026. The decision is designed to address an immediate compliance issue with Nasdaq while simultaneously clearing the runway for one of the most ambitious pivots seen in small-cap biotech in recent years.

The mechanics are straightforward. Outstanding shares will be reduced from approximately 11.4 million to 1.14 million. Authorised share capital remains unchanged, meaning the company retains significant flexibility to issue new shares in the future — a detail that will matter considerably as the proposed reverse takeover of Realbotix LLC unfolds.

The compliance rationale is standard fare. Nasdaq's minimum bid price requirement of $1.00 per share has ensnared dozens of micro-cap companies over the past two years, particularly those in the biotech and healthcare space where cash burn and investor sentiment have weighed heavily on share prices. For ONCO, the reverse split is the fastest available mechanism to restore compliance and avoid the reputational and operational damage of a Nasdaq delisting.

But the more consequential story is what comes next. Onconetix (NASDAQ: ONCO) has announced a pending reverse takeover transaction to acquire and list Realbotix LLC — a company specialising in AI-powered humanoid robotics. This represents a near-total transformation of the company's identity, from oncology-focused pharmaceutical developer to a player in what is arguably the most hotly anticipated technology category of the decade.

Humanoid robotics has captured the imagination of investors following high-profile developments from companies including Tesla and Figure AI, though the sector remains nascent and commercially unproven at scale. Realbotix brings a specific focus on AI-powered humanoid systems, a niche that sits at the intersection of embodied AI, human-machine interaction and autonomous systems — all areas attracting substantial venture and strategic capital.

For existing ONCO shareholders, the transaction raises important questions. Reverse takeovers of this nature involve significant dilution risk, regulatory complexity and execution uncertainty. The company's oncology pipeline, whatever its stage, is effectively being set aside in favour of a Business with an entirely different Capital Structure, Revenue profile and competitive landscape. Investors should approach the situation with clear eyes about what they are buying: not a biotech recovery story, but a speculative bet on a robotics business using a listed shell as its public market vehicle.

That said, the structure is not without precedent. Several successful technology companies have used reverse mergers to access public markets more quickly than a traditional IPO would allow, particularly in environments where direct listings and SPACs have faced increased regulatory scrutiny. If Realbotix has genuine technology, revenue traction or defensible intellectual property, the ONCO shell could prove a useful vehicle.

The timing of the split — ahead of the reverse takeover closing — suggests management is prioritising compliance to ensure the listing remains viable. A Nasdaq-Delisted company attempting a Reverse merger faces a considerably more complex path.

For investors watching ONCO, the next key milestones will be disclosure of Realbotix's financials, the terms of the reverse takeover, and regulatory approval from Nasdaq for the combined entity. Until those details emerge, the stock remains highly speculative.